As of January 22, 2025, Novartis (NVS) has a market cap of $197.89 billion USD. According to our data, Novartis is ranked No.69 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $197.89 B |
1.72%
|
Dec 31, 2024 | $194.55 B |
0.06%
|
Dec 29, 2023 | $194.44 B |
16.14%
|
Dec 30, 2022 | $167.42 B |
8.06%
|
Dec 31, 2021 | $154.94 B |
-3.65%
|
Dec 31, 2020 | $160.81 B |
3.34%
|
Dec 31, 2019 | $155.61 B |
27.13%
|
Dec 31, 2018 | $122.40 B |
5.95%
|
Dec 29, 2017 | $115.53 B |
19.46%
|
Dec 30, 2016 | $96.71 B |
-12.04%
|
Dec 31, 2015 | $109.95 B |
-4.52%
|
Dec 31, 2014 | $115.15 B |
19.16%
|
Dec 31, 2013 | $96.63 B |
31.81%
|
Dec 31, 2012 | $73.31 B |
15.67%
|
Dec 30, 2011 | $63.38 B |
1.14%
|
Dec 31, 2010 | $62.67 B |
12.32%
|
Dec 31, 2009 | $55.79 B |
14.25%
|
Dec 31, 2008 | $48.83 B |
-5.62%
|
Dec 31, 2007 | $51.74 B |
-3.54%
|
Dec 29, 2006 | $53.64 B |
11.26%
|
Dec 30, 2005 | $48.21 B |
3.84%
|
Dec 31, 2004 | $46.43 B |
12.13%
|
Dec 31, 2003 | $41.41 B |
27.34%
|
Dec 31, 2002 | $32.52 B |
1.98%
|
Dec 31, 2001 | $31.88 B |
-17.35%
|
Dec 29, 2000 | $38.58 B |
25.57%
|
Dec 31, 1999 | $30.72 B |
-25.26%
|
Dec 31, 1998 | $41.10 B |
20.43%
|
Dec 31, 1997 | $34.13 B |
41.52%
|
Dec 31, 1996 | $24.12 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Pfizer
PFE
|
$149.69 B |
-1.275 B
|
USA
|
Merck
MRK
|
$242.90 B |
-0.007 M
|
USA
|
Johnson & Johnson
JNJ
|
$344.10 B |
0.003 M
|
USA
|
GlaxoSmithKline
GSK
|
$68.73 B |
-0.194 B
|
UK
|
Sanofi
SNY
|
$129.28 B |
-0.313 B
|
France
|
AstraZeneca
AZN
|
$211.74 B |
0.000 M
|
UK
|
Bristol-Myers Squibb
BMY
|
$114.88 B |
-0.811 B
|
USA
|
AbbVie
ABBV
|
$298.08 B |
-0.039 B
|
USA
|
Eli Lilly
LLY
|
$679.60 B |
0.019 M
|
USA
|
Amgen
AMGN
|
$147.39 B |
-0.333 B
|
USA
|
Takeda Pharmaceutical
TAK
|
$41.29 B |
-0.238 B
|
Japan
|
Biogen
BIIB
|
$20.75 B |
0.203 B
|
USA
|
Gilead Sciences
GILD
|
$115.25 B |
-0.604 B
|
USA
|
Market Cap | = | NVS Stock Price | * | NVS Shares Outstanding |
= | $98.98 | * | 2.00 B | |
= | $197.89 B |